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Abstract European genetic testing guidelines recommend
that healthcare professionals (HCPs) discuss the familial im-
plications of any test with a patient and offer written material
to help them share the information with family members.
Giving patients these Bfamily letters^ to alert any relatives of
their risk has become part of standard practice and has gone
relatively unquestioned over the years. Communication with
at-risk relatives will become an increasingly pressing issue as
mainstream and routine practice incorporates broad genome
tests and as the number of findings potentially relevant to
relatives increases. This study therefore explores problems
around the use of family letters to communicate about genetic
risk. We conducted 16 focus groups with 80 HCPs, and 35
interviews with patients, recruited from across the UK. Data
were analyzed thematically and we constructed four themes:
1) HCPs writing family letters: how to write them and why?,
2) Patients’ issues with handing out family letters, 3)
Dissemination becomes an uncontrolled form of communica-
tion, and 4)When the relative has the letter, is the patient’s and
HCP’s duty discharged? We conclude by suggesting alterna-
tive and supplementary methods of communication, for exam-
ple through digital tools, and propose that in comparison to
communication by family letter, direct contact by HCPs might
be a more appropriate and successful option.
Keywords Family communication . Genomics . Inherited
genetic conditions
Introduction
Patients diagnosed with an inherited risk generally perceive
that they have a responsibility to tell their at-risk relatives
(Chivers-Seymour et al. 2010; Dheensa et al. 2016;
Hallowell et al. 2003). Healthcare professionals (HCPs) sim-
ilarly feel a responsibility to ensure these relatives are made
aware of their risk (Dheensa et al. 2015). European genetic
testing guidelines recommend that HCPs discuss the familial
implications of any test with a patient, as well as a strategy on
how to tell relatives. They advise genetic counselors to offer
the patients Bwritten material to help the counselee to spread
the information in the family^ (Kääriäinen et al. 2009).
Offering letters, often called family letters, to patients to give
to their relatives is a common way for HCPs to facilitate com-
munication and help to ensure that those at risk gain appropri-
ate information to allow them to make informed choices about
whether to seek advice about having a genetic test themselves
(Mendes et al. 2016; Ormondroyd et al. 2014; Wilson and
Etchegary 2010). Neither European nor British Society for
Genetic Medicine guidelines suggests a standard or a template
for a family letter (Joint Committee on Medical Genetics
2011). In general, letters inform the recipients about the famil-
ial inheritance and encourage relatives to seek a referral to
discuss testing. Figure 1 shows an example of a letter.
Although European guidelines mention written material,
the way that family letters are used in different countries is
unclear. UK genetic HCPs often write generic letters without
specifying to the patient who the recipients should be, mean-
ing this is left for patients to work out. In the Netherlands,
genetic HCPs specify the relatives to whom patients should
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give letters (I van Langen, personal communication,
Aug 2017). In a Dutch study about the dissemination of these
letters, 56 cardiogenetics patients were asked to distribute 249
letters and the number of at-risk relatives referred to the clin-
ical geneticist and/or cardiologist within two years was fairly
high at 57% (142 of 249) (van der Roest et al. 2009). This
suggests that the use of letters can be somewhat effective.
However, a number of studies about family communication
have shown that patients do not always tell their relatives
about a risk, and that this is for a range of reasons. These
include feeling a desire to protect oneself and family from
potentially harmful information and/or having a dysfunctional
relationship with the relative, lack of contact or closeness with
them, or poor understanding about the risk and its relevance to
others (Chivers-Seymour et al. 2010; Mendes et al. 2017;
Wiens et al. 2013). Thus, other ways for HCPs to help to
ensure that relatives become aware of their risk have been
suggested in the literature. For example, De Geus et al.
(2016) have tested the feasibility of an intervention that uses
motivational interviewing principles to improving hereditary
cancer counselees’ knowledge about which at-risk relatives to
inform and what information to disclose. Several other inter-
vention studies have offered additional genetic counseling or
family therapy about family communication for a range of
conditions, and these have significantly increased the number
of relatives told about their risk (Eisler et al. 2016; Forrest
et al. 2008; Hodgson et al. 2016). For example, Hodgson
et al. (2016) found, through a randomized controlled trial, that
communication of risk to relatives was higher for patients who
were given a specifically designed telephone counseling inter-
vention. In a different study, Eisler et al. (2016) delivered an
intervention based on family therapy principles to help
To whom it may concern,
This letter tells you about an inherited condition identified in your family that you may be 
at risk of. It briefly outlines the steps you can take to find out more about it.
Identification of a BRCA1 gene fault
A member of your family has been diagnosed with a genetic condition that causes an 
increased risk of cancer. Blood relatives could also have inherited the same gene fault. This 
letter is to advise all blood relatives about the gene fault and what further action should be 
taken.
What effect does the faulty gene have?
For women who have inherited a BRCA1 gene fault, there is a high likelihood of developing
breast or ovarian cancers. Men have an increased risk of breast cancer and a small 
increased risk of prostate cancer. Not all women who have a BRCA1 fault will develop 
cancer and we do not yet know why some do and some do not. The main thing to take note 
of is that the chances of cancer are higher than average, so early screening and or 
treatments might be recommended.
What chance do family members have of inheriting the gene fault?
A gene carrier will pass the faulty gene on to 50% (1 in 2) children on average. Male and 
female children have the same risk of inheriting the gene fault, although the consequences 
of the faulty gene differ between males and females. If a person does not carry the gene 
fault, then they cannot pass it on to their children.
What action should I take?
Genetic testing can accurately tell whether or not you have inherited the gene fault. The 
test tells you about your risk; it cannot tell you exactly when or which of the cancers might 
develop. If you are at an increased risk, you might benefit from extra medical checks or 
other measures to reduce cancer risk.
Further advice about check-ups and genetic testing can be obtained by asking your GP to 
refer you to your regional genetics service. You are welcome to contact me on the above 
number if you have any questions about this or if you need any further details in order to 
obtain a referral.
Yours sincerely,
Fig. 1 Example of a letter
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families cope with and talk about their genetic condition with
family members. They trained genetic counselors to runmulti-
family discussion groups in which different families could
learn from and support each other. The researchers found that
families thought the intervention valuable, acceptable and fea-
sible. A limitation is that some genetic services might be un-
able to incorporate these specific interventions due to
constrained resources and, for example, a lack of access to
family therapy expertise (Eiser et al. 2016). Thus, HCPs might
rely upon family letters. Interestingly, in the final stage of an
intervention by Forrest et al. (2008), 8/11 index patients had
not yet told their relatives about the risk. The researchers of-
fered these eight participants a family letter and the option for
a HCP to hand it out for them. Only three participants accepted
a letter and all three opted to hand it out themselves. The paper
gives no further detail about the letters.
Several other intervention studies have focused on the
use of letters more specifically and have shown that when
HCPs send letters directly to relatives, testing uptake sig-
nificantly increases (Evans et al. 2009; Suthers et al.
2006). In families with familial breast and ovarian cancer,
hereditary non-polyposis colorectal cancer, or Cowden
syndrome, Suthers et al. (2006) found that in usual prac-
tice (i.e. patients giving out letters), an average of 23% of
relatives in each family had a genetic test after two years,
compared with 40% in the intervention group (HCPs
sending relatives letters directly). Evans et al. (2009),
who contacted relatives about BRCA1/2 mutations, found
that uptake after direct contact by HCPs was especially
higher among men. Another study about hereditary colon
cancer showed that direct contact by HCPs led to testing
uptake that was comparable to contact by patients (Aktan-
Collan et al. 2007).
Although some genetic services feel obliged to contact at-
risk relatives directly to alert them of their risk (van der Roest
et al. 2009), a qualitative study about UK clinical genetics
practice showed that only a minority of HCPs would consider
making direct contact with the relative (or their GP) even
when a patient had specifically asked them to (Dheensa
et al. 2017). HCPs preferred to rely on patients to pass on
the information for various reasons: doing so arguably en-
hanced their patient’s autonomy (patients get to decide when
and how exactly to pass on the message). HCPs furthermore
argued that relying on patients to communicate would be bet-
ter for their own relationship with their patient, and their pa-
tients’ relationship with their family members. Specifically,
they worried that contacting relatives could amount to
Binterfering^ in family relationships, which could cause or
exacerbate any existing family tensions. Moreover, they con-
sidered patients to be better placed than themselves to tell
relatives because they would often have a relationship with
them, so would know how best to communicate with them
and how they might react. HCPs additionally argued that it
would be too resource-intensive to do anything other than give
their patient these letters. In cases where the patient was re-
fusing to tell their relatives, or where it was unclear whether
the patient had told them, HCPs worried that direct contact
would breach patient confidentiality.
For these reasons, the practice of giving family letters to
patients has gone relatively unquestioned over the years. In
fact, recently there have been suggestions for, and shifts
towards, expanding the use of letters. For example, Baars
et al. (2016) recently proposed giving letters to counselees
with a negative BRCA result as a means of giving them
some support. Furthermore, a recent case of non-
disclosure of a BRCA risk in a family in the Netherlands
has placed more pressure on HCPs there to ensure relatives
are aware of their risk, often via these letters (Vrijenhoek
2015). Finally, in France, legislation has been passed that
obliges HCPs to give their patients these let ters
(D’Audiffret Van Haecke and de Montgolfier 2016). Yet
studies show that communication often fails (Dheensa
et al. 2015). This suggests relying on patient-mediated let-
ters needs investigation.
It is a particularly timely point to explore the use of
family letters as the primary means of ensuring communi-
cation. Worldwide, projects such as the UK 100,000 ge-
nomes project, are underway, which aim to incorporate
whole-genome approaches into cl inical pract ice
(Caulfield 2016). Such testing is starting to be offered out-
side the genetics clinic, by HCPs for whom communication
with family members is new territory (Caulfield 2016).
Results from genome tests, at least initially, will make
communication with family members even more impor-
tant: HCPs will often need to test family members to de-
termine the significance of genetic findings or to contact
at-risk relatives about so-called incidental findings in fam-
ilies where there is no typical family history of the condi-
tion (Shkedi-Rafid et al. 2014). These questions are timely
also because cases where communication about genetic
risk has failed to happen have reached UK courts, raising
issues about HCPs’ responsibilities to relatives (Chico
2016; Fay 2016; Gilbar and Foster 2016; Mitchell et al.
2016).
Purpose of the Study
This paper aims to explore problems around the use of fam-
ily letters to communicate about genetic risk. To give our
study focus, we examined communication between adults,
firstly because communication with children would not
happen by letter, and because a body of literature has al-
ready explored the unique issues raised when parents com-
municate risk information to children (e.g., Eisler et al.
2016; Metcalfe et al. 2011; Plumridge et al. 2011;
Rowland and Metcalfe 2013). Originally, the focus groups
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and interviews were organized as part of a study that aimed
to explore patients and HCPs’ views and experiences of
consent, confidentiality, and sharing information in genetic
medicine. Some of the specific research questions included
whether HCPs and patients consider genetic information as
confidential at the individual or familial level and whether
they perceive HCPs to have a responsibility to patients’
relatives (Dheensa et al. 2015, 2016, 2017). Much of the
resultant data provided novel insight into familial commu-
nication, including the use of letters.
Methods
Recruitment and Sample
There were two participant groups: HCPs and Bpatients^: peo-
ple who have had a genetic test and/or are affected by the
signs, symptoms, and routine surveillance associated with a
condition. One exception was P34 whose spouse had died
from a Lynch syndrome cancer, whose children were at risk,
and who requested an interview.
We invited HCPs who order genetic tests to take part
through presentations at professional meetings and by sending
emails with attached information sheets to heads of depart-
ments for dissemination to colleagues. Sampling was purpo-
sive: the aim was to recruit from a range of genetic and affil-
iated services. Since HCPs work and make decisions in teams,
we chose cross-sectional (one-off) focus groups instead of
interviews, with groups working in the same department
where possible, to provide an understanding of the real-life
context in which HCPs worked (Vaughn et al. 2006). We held
16 focus groups with 80 HCPs from across the UK, either in
clinical departments or during professional meetings. Table 1
contains details of their professions. We have a relatively high
number of focus groups because in the UK there are 23 genet-
ic centers, as well as one cancer center that conducts genetic
testing routinely. In the original study, we wanted to gain a
picture of local practices in as many centers as possible—our
HCP participants came from 14 of the 24 centers. It is worth
noting here that there were no striking differences between
centers regarding the use of letters.
Local collaborators helped to recruit patients via three large
UK genetics centers (who posted information about the study
onwards to all recent patients seen for conditions amenable to
intervention, such as hereditary cancers and cardiac conditions, in
the previous two years) We also posted study information on
social media sites for specific conditions and for genetic condi-
tions generally. Although one Bpatient^ participant had a
Huntington disease test, we focused on conditions conventional-
ly thought of as amenable to medical intervention (e.g. familial
cancers and cardiac conditions where there is treatment, risk-
reducing option, or surveillance), since here, communication
with at-risk relatives is most urgent. Since patients lived in dif-
ferent parts of the country, had different conditions, and had
potentially sensitive experiences to discuss, we offered inter-
views rather than participation in focus groups. SD (the first
author, a social scientist with expertise in the ethical and social
aspects of genetics/genomics) contacted those who sent back an
expression of interest slip or responded online to arrange a suit-
able time and date and, for face-to-face interviews, a suitable
location. There were 35 adult participants from England (one
of whom was also a HCP in FG14). Table 2 contains details of
patient participants’ genders, conditions, test results, and issues
they faced regarding communication about the risk.
Data Collection
SD conducted all audio recorded focus groups/interviews,
which lasted approximately one hour. Since focus groups
comprised on average just five participants, we did not con-
sider it necessary to involve an observer—SD fulfilled what
would be an observer’s role (e.g., taking field notes of non-
verbal communication, such as nodding). A limitation of this
approach is that some observational data might have been
missed (Stewart and Shamdasani 2014). The interview sched-
ule and topic guide (provided in Table 3) were adapted over
time to pursue emerging lines of inquiry. We ceased recruit-
ment and data collection as we approached saturation: when
the main categories had depth and variation (Corbin and
Strauss 2015). Data were generated between late 2013 and
early 2015.
Data Analysis
To analyze data, we drew on a thematic analysis method
(Braun and Clarke 2006). All three authors (SD, AF, a social
Table 1 Professions represented across the focus groups
Profession n
Genetic counselors 37
Clinical scientists (molecular/cytogenetics) 16
Consultants in clinical genetics 8
Registrars (trainees) in clinical genetics 8
Nurses working with a genetics team 4
Fetal medicine professionals 4
Family history coordinators 2
Nephrologist 1
Total 80
Of the 16 professional focus groups (FGs) in this study, FGs 5, 6 and 7
comprised of genetic counselors who worked in different genetic centers.
In all other FGs, all participants worked in the same team as each other.
FG2 and FG9 comprised of clinical laboratory scientists (molecular or
cytogeneticists)
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scientist with expertise in medical ethics, and AL, a consultant
in clinical genetics with expertise in the ethical aspects of
genetics/genomics) participated in coding and constructing
themes. We initially analyzed the datasets (HCPs and patients)
separately. Analysis involved repeatedly reading transcripts,
coding data, and creating themes. More specifically, we went
through the data line by line, labelled salient features with
codes, and identified key questions and potential themes. To
Table 2 Demographic characteristics of patient participants (N = 35)
Variable Number of participants
Gender 24 women (W); 11 men (M)
Test status 31/35 had tested positive for their condition. Of the remaining five:
− 2/35 had tested negative (P8,cardiomyopathy,W and P11,Huntington,W)
− 2/35 had not yet had a test but were undergoing surveillance (P5, possible Lynch,W and P12,HBOC,W)
− 1/35 was the partner of patient who died of a Lynch syndrome related cancer and had at -risk children (P34,Lynch,W)
Condition/risk Hereditary breast/ovarian cancer (HBOC): 14/35 (5/14 had a diagnostic test after cancer)
Lynch syndrome: 9/35 (7/9 had diagnostic test after a cancer)
Familial Adenomatous Polyposis (FAP): 3/35 (1/3 had a diagnostic test after a cancer)
Alport syndrome: 4/35
Hereditary cardiomyopathy: 2/35
Hereditary haemochromatosis: 1/35
Huntington disease: 1/35
Undisclosed: 1/35 (HCP who was also a patient)
Learning about risk Most learned of their risk at the same time as siblings and other close relatives. 7/35 were probands and told family
about their risk immediately, often before having a test/getting their result
Disclosure None had withheld information although a few had not told distant relatives yet, mostly because they had no contact details.
Three participants’ relatives did not share information about risk with them.
P5 (possible Lynch,W): cousin was withholding his exact mutation so she could not have a definitive test.
P18 (HBOC,W): sister did not want to tell her about risk directly so asked her General Practitioner (GP) to do so.
P18 found out months later as GP failed to pass the message on.
P30 (HBOC,W): sister did not share her HBOC diagnosis. P30 found out because a nurse mentioned it during an a
ppointment with the affected sister, which a third sister attended. The third sister then told P30 about the risk.
Table 3 Topic guide and interview schedule
Group Questions
HCPs • Introductory questions (e.g., what is your role? What kinds of patients do you see? How many per week?)
• Is confidentiality important in the area of medicine that you are working in?
• What aspects of the medical consultation should be kept confidential?
• Are there guidance documents or protocols you follow for confidentiality?
• How, if at all, do you talk about the limits of confidentiality in the consent process?
• Regarding genetic test results, who do you think should be the one to tell the result to at-risk relatives?
• Have you ever had experience of a patient telling you they were not going to inform their family of risk? Or a patient who you weren’t sure
had told?
• To what extent do you feel like you have a responsibility to make sure patients’ family members know they are at risk?
• Regarding these issues, do you feel like you have enough support and training?
• Who do you talk to about ethical issues?
• What are your main ethical concerns, if you have any?
• Do you have some other things you would like to raise?
Patients • Introductory questions (e.g., tell me about yourself)
• Can you start by telling me why you first thought about having a genetic test?
• How did you feel before you went to talk to the genetics team?
• What made you decide to have the test/not to have the test?
• (Where relevant) Can you tell me what it was like receiving your results?
• What do you think happens to your test result?
• What does privacy/confidentiality/secrecy mean to you?
• Whose responsibility is it to tell at-risk family members of risk?
• What are your hopes and concerns about genetic testing?
• Do you have some things you would like to add?
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combine the data from the two groups, we used an adapted
version of the Bfollowing a thread^ method, which is used in
mixed-methods studies: we selected certain codes and poten-
tial themes (Bthreads^) from one dataset and investigated the
way they were discussed in the other (Moran-Ellis et al. 2006;
O’Cathain et al. 2010). The other dataset raised additional
questions and ideas about the code or potential theme, which
we then explored further by going back to the first dataset. We
thus moved iteratively, back-and-forth, between the two
datasets, which allowed us to identify areas of convergence
and complementarity, as well as divergence. During this pro-
cess, we built up our codes into themes and then reviewed the
themes to ensure they accurately reflected the codes. Ongoing
analysis helped us to refine the themes and the overall narra-
tive of our data. All authors critically reviewed the thematic
story to improve the rigor—specifically the credibility and
confirmability—of the analysis.
Results
The resultant themes reflect each step involved in communi-
cation by letter: 1) HCPs writing family letters: how to write
them and why?, 2) Patients’ issues with handing out family
letters, 3) Dissemination becomes an uncontrolled form of
communication, and 4) When the relative has the letter, is
the patient’s and HCP’s duty discharged? In the quotes below,
patients and professionals’ names are replaced with identifi-
cation codes (e.g., focus group 1 participant 1 = FG1P1, pa-
tient 1 = P1). We also indicate the patients’ condition and
gender (with M for man and W for woman).
Theme 1: HCPs Writing Family Letters: How to Write
Them and Why?
HCPs struggled with how to word family letters: whether it
was appropriate to use wording that told at-risk relatives, di-
rectly, to seek a test, or whether to leave this decision up to
them. That is, they worried about how directive they should
be, especially as they could not know which relatives the
patient would disseminate the letter to (and in turn, whether
testing could actually be helpful for the recipient). HCPs also
worried that letters might frighten recipients:
FG1P4: Our letters are quite gentle, BWe’ve seen a fam-
ily member and some people might be at risk, if you
want to find out if you’re one of those people, get in
touch^. [Colleague] received a letter from another ge-
netics service, that said, BYou’re probably aware of the
gene mutation that’s been found in your family, if not,
this is probably going to be really distressing for you to
read.^
FG1P5: That was the first paragraph…
FG1P4: That was the opening paragraph. As long as
you’re not giving someone a letter that says, BThis is
terrible news.^
FG1P5: BThis is a death sentence.^
While a letter that told relatives they were at risk might
make them too frightened to seek a referral, one that was
vague might not lead them to seek a referral at all:
FG14P1: The wording can have quite an influence on
whether someone does then act on it.
FG14P4: You don’t write anything to scare the living day-
lights out of them.Youwrite a gentle letter…It’s difficult to
know how forceful to be, BYou must go and be seen.^
FG14P1: It’s trying to strike a balance between not
frightening someone, but making them aware that it’s
important information that could be relevant to them and
change things.
FG14P4: But it’s hard because you’ve never met this
person and you don’t know how they’re going to re-
spond to the letter.
FG14P3: Yeah, everyone will read it differently. Some
people will interpret it as, BThat’s something I could
do,^ and others as, BThis is a thing I must do.^
HCPs also pointed out that the reading age of the letters
they wrote was probably too high [FG4P1] and so the infor-
mation would likely need further explanation at a clinic ap-
pointment. These kinds of considerations were important to
HCPs because once they identified an inherited tendency in
their patient, they felt responsible for telling at-risk relatives
who might also have inherited the same condition. Using a
letter was their way of acting on this responsibility. As the
quotations above suggest, they acknowledged that the letter
was not an optimal way to communicate, but they did identify
some benefits of using them. For example, they thought that
the letter would at least Bmake it easier^ for patients to com-
municate with relatives because that having written informa-
tion would boost their confidence, which could in turn make it
more likely that they would talk to relatives about the risk:
FG7P3: I use letters a lot, BPass these on to your relatives.^
I’m quite surprised at the difference in confidence that
people have. They feel they’ve got some backup. People
are scared of getting information wrong when they pass it
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on. It’s about that making it easy to share information. I
think that’s where we can really focus our efforts.
Patients echoed this and told their relatives to read the letter
for an explanation of the risk;
P17: I said [to my children], BIf you read the letter, it’ll
explain it.^ (M, Lynch)
Theme 2: Patients’ Issues with Handing out Family
Letters
While HCPs thought the letter would be helpful for patients,
patients did not always agree. They thought the letter was
more helpful for their GPs:
P34: I didn’t think that there was any…the only reason
behind that letter was just the ticket to get your GP to do
something for you. (W,Lynch)
Other patients saw the letter as having symbolic value; once
they had been given it, they felt pressured to tell their relatives
about the risk. Importantly, they also felt they were obliged,
where possible, to have a conversationwith their relatives or send
them an accompanying letter or email of their own. This obliga-
tion extended to relatives with whom they had no, or a poor,
relationship. They felt uncomfortable about giving relatives the
letter unexpectedly as this could cause the recipient to become
distressed or anxious:
P26: If I hadn’t told them and they suddenly got some-
thing out of the blue through the post, they would have
wondered why I hadn’t said anything…there are some
who obviously may find it very difficult. (W,BRCA)
One HCP corroborated these patients’ views, i.e., receiving a
letter could be upsetting: FG5P1 reported having received a
Bseries of angry phone calls^ from relatives of a patient who
had posted the letters, without explanation, enclosed in
Christmas cards.
HCPs recognized that for patients, having this conversation
with relatives, or writing them a personalized letter or email,
took Ba huge amount of emotional energy and thought, time,
and care^ [FG8P1]. Indeed, patient participants reported that
planning their strategy for communication with at-risk rela-
tives and dealing with the consequences of communication
was extremely difficult, as one participant—who was both a
patient and a HCP member of FG14—highlighted:
P35: The logistics of doing that and the problems it can
cause. It’s ended up in people not speaking in the family,
and then you’re left, as the person disseminating that
letter, with that. I’ve decided to give the letter to my
brothers, and I know all my nephews have not been told.
And I love my nephews. I am put now in a very difficult
position. (W,undisclosed condition)
While many of these are issues relevant to communi-
cating genetic findings within families in general, the
findings showed that the use of letters was not helpful
for solving problems, and in fact, using them could create
more problems. For example, the above quotation high-
lights how patients handing out letters could end up be-
coming complicit in keeping family secrets because gate-
keepers in the family could block the letter and further
communication. Since handing out the letters and talking
to at-risk relatives was so emotionally distressing, one
patient argued that it Bshouldn’t be up to^ her and thought
HCPs should have told her relatives instead:
P9: It was horrible circumstances, a funeral. I’ve got a
younger sister, but we don’t know who her dad is [and
whether she’s at risk]. I didn’t want her to find out
through a letter, and I haven’t spoken to her for years,
so I was put in this predicament where I had to speak to
her. I was angry. I’ve got enough to deal with, and I’m
having to worry about telling everybody in my family,
and it shouldn’t be up to me. I could be dead by the age
of 40, and yet I’m expected to deliver this, deliver that,
find this address, go through this person, go through…
the arguments it caused….(W,FAP)
HCPs knew that patients were communicating in these
difficult circumstances. They pointed out another difficul-
ty: that at-risk relatives might Boverreact^ to the news of a
risk, leaving patients to deal with the additional responsi-
bility of trying to Beducate^ them. HCPs remarked that
the prospect of this led some patients not to talk to rela-
tives at all:
FG6P3: Some people don’t want to share because it’s
going to be blown out of all proportion, and for some
quite treatable conditions—some bleeding conditions,
there is treatment, it can be managed well—yet they
don’t want to share that with their family. They say it’s
going to be turned into something that it’s not, which
you hear a lot, or I hear a lot, in clinic.
Patients were thus triply burdened: burdened with their
own diagnosis, with the emotional and practical effort of com-
municating, and with causing and managing arguments and
secrets. As the quotation below illustrates, any notion that
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patients might Blike^ the responsibility of disseminating infor-
mation (e.g., because it would endow a sense of control) was
quickly countered in the focus groups, because HCPs knew
that communication was onerous:
FG8P5: Do you think people like that responsibility [of
sending letters] though? Or do you think they actually
feel then they have to be the messenger and get shot?
FG8P1: I think it’s a real burden for some of them,
absolutely.
FG8P5: I sometimes worry a bit about that.
FG8P3: The people that they don’t know or haven’t seen
for ages, then they suddenly have this party or wedding
and then they go distributing these letters. Sometimes
it’s the only chance they’ll have.
FG8P4: It’s not ideal.
FG8P2: Often at funerals.
Despite this, many HCPs did not think that sending letters
directly to at-risk relatives was an appropriate part of their
role, for a range of reasons such as worrying about the ethical
aspects, and social implications, of approaching people to
whom they had no duty of care. For example, they worried
about not knowing the intricacies of family dynamics and that
direct contact might worsen any existing conflicts:
FG13P2: If a patient’s not prepared to communicate
with family members, there’s already a dynamic issue
there. I don’t want to be responsible for potentially mak-
ing that worse.
Another participant worried that a letter from a HCP might
place influence on a relative to have a test:
FG2P3: The clinical geneticists, I don’t think they’re
allowed, they can’t go out and tout for business.
Theme 3: Dissemination Becomes an Uncontrolled Form
of Communication
HCPs highlighted two examples of how the letter could
became an uncontrolled form of communication. The first
example was that some patients passed letters on too
widely—to relatives at no risk or minimal risk. Patients
might do this due to a misunderstanding or due to taking a
Bbetter safe than sorry^ approach. Notably, HCPs said that
sometimes, these relatives were referred in to see them
and wanted a test. HCPs said they felt conflicted about
whether they ought to test them, given their potentially
low risk and that testing them could reveal the result of
an intervening relative. HCPs tried to obviate these issues
by specifying the relatives that patients needed to tell.
However, patients’ faulty interpretations of risk were dif-
ficult to undo:
FG14P8: [Whether and to whom they pass on the letter]
can be [based on] so many sets of objectives and
thoughts about what they’ve had in the family. It might
be, therefore, if they disseminate it within the family,
they still just disseminate with [the idea that] Bit’s al-
ways been the blokes^, Balways been the girls^, and
so on, and it’s really hard to get rid of that, I think.
A second example came from FG8, in which a mother took
some letters from her daughter without permission. Here, the
loss of control manifested in the patient not being in control of
whom to tell and when:
FG8P1: I had a patient with a BRCA mutation. Her
mum hadn’t had testing: we didn’t know whether it
had come down mum’s side. The mum took it upon on
herself to let everybody know, to hand out letters at the
exit of the church at a funeral or some family gathering.
So, my patient is furious: she felt that was her informa-
tion to give and [that it was] her right to choose when
she gave that information. She felt a lot of guilt that it
had started with her. It’s created real family conflict.
This HCP pointed out that the patient’s mother’s actions can
be seen as particularly undermining of the daughter when
considering the time and care that patients usually put into
telling relatives about the risk.
Theme 4: When the Relative Has the Letter, Is
the Patient’s and HCP’s Duty Discharged?
Like proband patients, participants who had received family
letters themselves talked about how having a letter created a
sense of obligation. In this case, the obligation was to seek
testing, if only to help their relatives. A quote from P22, who
had female grandchildren, illustrates this point:
P22 I was informed by this letter that my sister gave to
me. It was a formal introduction to faulty BRCA gene.
So then, I thought about it and I decided I had to take the
test. I couldn’t ignore the fact that this process had been
initiated. Having had the letter, I had to take the test, in
my view. I couldn’t ignore it, for the sake of potentially
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other people in the family …Having been informed
about it transmit[ted] a pressure to take the test.
(M,BRCA)
Some participants who were probands said that unlike P22,
their relatives did not seek a referral upon reading the letter.
Some even declined the letter: the relatives were apparently
anxious and they coped with this anxiety through avoidance:
P9 I said to [cousin], BThere’s a chance it’s in the family;
do you want one of the letters?^. He said, BI don’t want to
know; I don’t need to know. I went to the doctors a couple
of weeks ago and I had a full MOT [check-up] and there’s
nothing wrong with me.^ The same with [another cousin],
BOh, I think I’d know by now if I was ill.^ I went, BOkay,
you can’t say I haven’t told you.^ (W,FAP)
This finding echoes HCPs’ worries: that letters worded too
strongly could frighten relatives, but being unspecific about
the risk might lead to apathy towards testing:
FG8P2: Some of the Bto whom^ letters are quite, not
vague, but you don’t want to give them risk figures,
because you don’t want to scare people. So, you keep
them quite simple.
As P9’s quotation above hints at, patients felt that once they
had talked to their relatives about the risk and handed on the
letter, to an extent, they had discharged their responsibility.
They had done all they could, having alerted them and talked
to them about the risk and referred them to the letter for more
information. They could not, and did not see it appropriate to,
Btalk their relatives into^ having the test, and the letter certain-
ly did not convince the relatives to do so:
P17: I said BIf you read the letter it’ll explain it, and it is
wise that you get checked yourself.^ My lad, he, he
don’t even talk. I asked my daughter, BHas he said
anything?^ I got BNo.^ So I just, I don’t honestly think
he’ll have it done.
I: Have you tried to convince him or do you think you
need to?
P17: No, I’ve said to him, BWell, I think you should
have it done, simply because you’ll be checked.^
(M,Lynch)
Avoidance might be easier or more likely if a letter is sent
without any accompanying discussion, but patients’
experiences indicated that even after such conversations, fam-
ily members may not take up the offer of testing. It is not clear
from these findings what the nature of the conversations were
and whether patients might have contributed to their relatives’
anxiety.
HCPs reflected that there was an over-reliance on letters,
and patients needed open channels through which they could
contact HCPs for help with communication:
FG8P1: We give the letters, and we trust that most fam-
ilies will pass it on, but we don’t routinely check who’s
been told and who hasn’t. We rely on them sharing that.
FG8P2: We rely on them [the patients].
HCPs worried that being handed letters symbolized some
Bfinality^ to patients—that the clinical encounter was over—
and thought there ought to be some way to remedy this:
FG14P8: No-one’s ever got back to me to say BI can’t
bring myself to [pass on letters].^
FG14P5: But there isn’t a pathway for that person to
know they can come back [to us].
FG14P1: I don’t think the patients get back to us nearly
as often as they could, or should. I think they just keep
quiet and lie low.
Some participants in this focus group wondered whether
there ought to be a Bfamily communication officer^ to see
patients six months after their diagnosis. P35, the patient-
HCP from FG14, agreed that options for follow up would be
helpful:
P35 It would have been nice to have had somebody to
come back to. Because I was left. I would have liked
somebody to have shared that burden, and to have said,
BThey’re not listening, I don’t know what to do, I’ve got
this knowledge, help me.^ (W,undisclosed condition).
Discussion
This study has explored some of the reasoning around, and
problems with, using family letters to communicate genetic
risk to at-risk relatives. Since the use of such letters has be-
come a standard practice where inherited tendencies are iden-
tified, and since they are likely to be used more as we enter the
Limitations and Pitfalls of Using Family Letters to Communicate Genetic Risk: a Qualitative Study with...
genomic age, our exploration is timely. We found that the
letter had several practical and symbolic functions. These in-
cluded boosting patients’ confidence when talking about the
risk to relatives; alerting a GP to the need for a referral to a
genetic service; placing pressure on probands to tell relatives;
placing pressure on relatives to have a genetic test; and as a
tool to help HCPs and patients discharge their moral duty to
relatives.
We found that there were difficulties at each step in the
process of using the letters. For example, when writing
them, HCPs worried about striking the balance between
encouraging relatives to have a test while indicating they
had a choice about having one, and worried about how to
word letters in a way that was clear but would not
cause alarm. This finding echoes previous research about
genetic counseling summary letters: compared with
shorter letters, specially written by medical writers, pa-
tients found letters written by HCPs too long and compli-
cated. They caused anxiety and lower perceived confi-
dence around understanding their condition (Brown et al.
2016; Roggenbuck et al. 2015).
When giving out letters, patients felt obliged to make con-
tact and talk with their relatives, recognizing the potential
harm of not doing so. Sometimes these were relatives with
whom they had no, or a poor, relationship. Patients saw this
task as more onerous and complex than simply Bpassing on^ a
letter. Previous research has framed this obligation to relatives
as a kind of genetic responsibility (e.g., Hallowell et al. 2003).
According to one systematic review, discharging responsibil-
ity towards family members and preventing illness are two of
the four core functions that communicating within families
about genetic risk serves. The other two functions are seeking
emotional support and advice and obtaining information from
the family (Wiseman et al. 2010). This same systematic re-
view showed that patients believed that they were responsible
for disseminating, or felt obliged to disseminate, genetic in-
formation. Similarly, participants in our study were tasked not
only with coping with their diagnosis or test result but also
with managing the consequences of telling relatives and ques-
tions of how much they should encourage relatives to have a
test. In a recent discussion-paper, illustrated with real life
cases, Mendes et al. (2017) highlight that patients navigating
these same questions can sometimes exert pressure on family
members to have a test out of a concern for their welfare. This
can threaten these family members’ autonomous decision-
making processes for whether to have a genetic test, which
in turn, can increase the risk of family conflict. HCPs in pre-
vious studies have expressed concerns that patients might ex-
ert pressure on relatives to have a test if communication is left
up to them (Stol et al. 2010). Like Mendes et al. (2017), we
found that handing out letters could lead to family tensions—
and this undermines some of HCPs’ arguments against
contacting at-risk relatives themselves, for example, that
patients often have a relationship with relatives that makes
them better placed than HCPs to communicate (Dheensa
et al. 2015, 2017; Stol et al. 2010).
Although HCPs aim was for the letters to benefit rela-
tives, they were rarely aware of whether and to whom let-
ters had been passed; and sometimes a letter, and thereby
the dissemination of information, was Bblocked^ by family
members or shared inappropriately. So-called blockers are
apparently common: one study with 183 women with
BRCA1/2 mutations showed that on average, each partici-
pant had one blocker in their family, tending to be the par-
ticipants’ male spouses/partners and first-degree relatives
(Koehly et al. 2009).
It is clear from these findings and previous research that
patients might need support when talking to relatives about
risk. However, as Mendes et al. (2016) point out, HCPs some-
times offer only information-based help—aiding patients’ un-
derstanding of their risk or condition—that focuses on the
individual, rather than the family unit. HCPs also indicate they
do not always address issues of family communication in their
practice (Forrest et al. 2010).
WhatMight Be some Useful Supplements to Using Family
Letters?
It is worth considering some alternative and supplementary
approaches to communication, which HCPs might discuss
with patients to determine which they prefer. For example,
HCPs might send letters directly to patients, which inter-
vention research has shown can lead to an increase in test-
ing uptake among at-risk relatives (Evans et al. 2009;
Suthers et al. 2006). Patients who want help would then
be relieved of the burden of communicating and HCPs
would be able to track whether relatives had been
contacted. These intervention studies are limited because
testing uptake is not necessarily the best marker of success-
ful communication. Relatives might still decide not to re-
spond to letters from HCPs—they might decide not to seek
testing, and letters might be frightening or too vague to
inspire action. Indeed, a substantial proportion of relatives
in the interventions that involved direct contact did not re-
spond to letters, and many did not have a genetic test. For
example, in Suthers et al.’s (2006) intervention cohort, on
average only 40% of eligible relatives who had received
letters from HCPs had their genetic status confirmed after
two years.
An alternative to using letters is for patients or HCPs to
contact at-risk relatives via web-based platforms, such as
Kintalk.org, which could be set up, with the patient’s
permission, to allow HCPs to contact relatives directly
and/or to see whether relatives have responded to the infor-
mation (Myers et al. 2013). BMyMedical Record^, an elec-
tronic health record launched in several UK National
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Health Service trusts, has the potential to be developed in
this way. Integrating such a tool into genetic practices
would align with the broader shift towards digitization
and integration of apps in healthcare services, but could
widen inequality between patients from higher and lower
socioeconomic status groups (Tudor-Hart 1971). There are
also implications for patient confidentiality (e.g., if some-
one could access a patient’s record without permission)
(Wynia and Dunn 2010). Many patients would still feel
obliged to talk to their relatives about the risk even if the
message was sent by a HCP or through an online tool. Thus,
there would still be the need for support in this regard.
Practice Implications
Based on these findings, we recommend that HCPs:
& help patients understand who should get the letters and
why, e.g., using the family pedigree.
& discuss with patients about how they would like commu-
nication to proceed and to consider alternatives and sup-
plements to standard practice.
& design letters with patient groups so that they are of an
appropriate reading age and strike the balance between
encouraging relatives to seek a referral without being
overly directive or alarming.
& consider making direct contact with relatives/their GP as
an alternative, or a supplement, to patients passing letters
on.
& make it easier for patients who want help with communi-
cation to recontact HCPs.
It is especially important to improve communication prac-
tices as healthcare services incorporate broad genome tests,
because these can produce a range of findings, including inci-
dental findings, which can be relevant to patients’ relatives.
Healthcare services plan to incorporate these tests into routine
practice, meaning an increase in the number of patients and at-
risk relatives is imminent. These tests will be ordered more
frequently by Bmainstream^ specialties for whom such issues
will be new territory, and who might need to liaise with clin-
ical genetic services. Most HCPs in our study had genetics
training and were thus well placed to assist families with com-
munication: further consideration is required as non-genetic
HCPs become more involved in ordering tests. Given all of
this, our work is continuing to see how we can develop My
Medical Record to improve familial communication.
Study Limitations
This study is the first to investigate the purpose, advantages,
and drawbacks of using family letters. Our study was limited
to the UK. This was for specific reasons: the country has a
national health service and a well-established genetic service,
where European recommendations guide practice about fam-
ily letters. We nevertheless call for research about practices
elsewhere.
Since this study did not originally set out to investigate
the use of letters specifically, some background data,
which would have been useful to contextualize our results,
was missing—for example, how many patients gave out or
received letters and level of experience of HCPs (as a
proxy for how experienced they were at writing and issu-
ing letters). We did not explore the issues around family
letters according to different conditions—further research
on this question could be useful.
As is common in qualitative research, a limitation is that
our sample was self-selected and thus potentially biased
towards people especially engaged with managing and
discussing their condition. This might explain why none
had refused to tell family members about their condition.
As Robinson (2014) points out, Bself-selection bias is not
possible to circumvent in interview-based research, as vol-
untary participation is central to ethical good practice,
therefore all a researcher can do is be aware of the possibil-
ity for bias and consider its possible impact on findings and
generalizability^ (p.36).
Conclusion
Several studies have explored the process of communica-
tion about genetic risk but none has explored the use of
family letters. In this study, participants perceived letters
to fulfill several roles but their journey from HCP, to pa-
tient, to relative was problematic. HCPs struggled to write
letters in a way that was easy to understand while informa-
tive and reassuring, and encouraging without being overly
directive. The letters helped patients in that they could refer
relatives to its contents for a better explanation about the
risk. However, communication was still fraught with diffi-
culties and the letters did little to ameliorate these. What’s
more, letters could be shared too widely, leading patients to
lose control over the information. HCPs realized that letters
could symbolize Bfinality^ to patients—that the clinical
encounter was over—and as such, HCPs thought that pa-
tients needed more support talking to relatives. We recom-
mend that HCPs talk to patients about alternative and sup-
plementary ways of communicating with relatives; that di-
rect contact might be more appropriate in some cases; and
that extra support is merited. These issues are pressing be-
cause mainstream specialties are now feeding back primary
and unexpected incidental findings from broad genome
tests. Patients will need support with talking to relatives
about ever-more complex information. Thus, the next stage
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of our work will involve the development of an online
resource to facilitate communication.
Acknowledgements Thank you to participants and the two reviewers
whose comments were invaluable for improving this manuscript.
Funding The project was funded by the UK Wellcome Trust
(WT088581MF).
Compliance with Ethical Standards
Ethics Approval and Consent to Participate All procedures per-
formed in studies involving human participants were in accordance with
the ethical standards of the institutional and/or national research commit-
tee and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards. This article does not contain any studies
with animals performed by any of the authors. Consent was obtained from
all individual participants included in the study. Ethics approval was
granted by the NHS South Central Hampshire Research Ethics
Committee. REC reference: 13/SC/0041.
Conflict of Interest All authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Aktan-Collan, K., Haukkala, A., Pylvänäinen, K., Järvinen, H. J.,
Aaltonen, L. A., Peltomäki, P., et al. (2007). Direct contact in invit-
ing high-risk members of hereditary colon cancer families to genetic
counselling and DNA testing. Journal of Medical Genetics, 44(11),
732–738.
Baars, J. E., Ausems, M. G., van Riel, E., Kars, M. C., & Bleiker, E. M.
(2016). Communication between breast cancer patients who re-
ceived inconclusive genetic test results and their daughters and sis-
ters years after testing. Journal of Genetic Counseling, 25(3), 461–
471.
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology.
Qualitative Research in Psychology, 3(2), 77–101.
Brown, E., Skinner, M., Ashley, S., Reed, K., & Dixon, S. D. (2016).
Assessment of the readability of genetic counseling patient letters.
Journal of Genetic Counseling, 25(3), 454–460.
Caulfield, M. (2016). 100,000 genome project. In S. Davies (Ed.),
Generation genome (p. 2017). London: Department of Health.
Chico, V. (2016). Non-disclosure of genetic risks: The case for develop-
ing legal wrongs. Medical Law International, 16(1–2), 3–26.
Chivers-Seymour, K., Addington-Hall, J., Lucassen, A. M., & Foster, C.
L. (2010). What facilitates or impedes family communication fol-
lowing genetic testing for cancer risk? A systematic review and
meta-synthesis of primary qualitative research. Journal of Genetic
Counseling, 19(4), 330–342.
Corbin, J., & Strauss, A. (2015). Basics of qualitative research, 4th edi-
tion. Newbury Park: Sage Publications.
D’Audiffret Van Haecke, D. A., & deMontgolfier, S. (2016). Genetic test
results and disclosure to family members: qualitative interviews of
healthcare professionals’ perceptions of ethical and professional is-
sues in France. Journal of Genetic Counseling, 25(3), 483–494.
de Geus, E., Eijzenga, W., Menko, F. H., Sijmons, R. H., de Haes, H. C.,
Aalfs, C. M., & Smets, E. M. (2016). Design and feasibility of an
intervention to support cancer genetic counselees in informing their
at-risk relatives. Journal of Genetic Counseling, 25(6), 1179–1187.
Dheensa, S., Fenwick, A., Shkedi-Rafid, S., Crawford, G., & Lucassen,
A. (2015). Health care professionals’ responsibility to patients’ rel-
atives in genetic medicine: a systematic review and synthesis of
empirical research. Genetics in Medicine, 18(4), 290–301.
Dheensa, S., Fenwick, A., & Lucassen, A. (2016). Is this knowledgemine
and nobody else’s? I don’t feel that.’ patient views about consent,
confidentiality and information-sharing in genetic medicine.
Journal of Medical Ethics, 42(3), 174–179.
Dheensa, S., Fenwick, A., & Lucassen, A. (2017). Approaching confi-
dentiality at a familial level in genomic medicine: a focus group
study with healthcare professionals. BMJ Open, 7(2), e012443.
Eisler, I., Ellison, M., Flinter, F., Grey, J., Hutchison, S., Jackson, C., et al.
(2016). Developing an intervention to facilitate family communica-
tion about inherited genetic conditions, and training genetic coun-
sellors in its delivery. European Journal of Human Genetics, 24(6),
794–802.
Evans, D. G. R., Binchy, A., Shenton, A., Hopwood, P., & Craufurd, D.
(2009). Comparison of proactive and usual approaches to offering
predictive testing for BRCA1/2 mutations in unaffected relatives.
Clinical Genetics, 75(2), 124–132.
Fay, M. (2016). Negligence, genetics and families A duty to disclose
actionable risks. Medical Law International, 16(3–4), 115–142.
Forrest, L. E., Burke, J., Bacic, S., & Amor, D. J. (2008). Increased
genetic counseling support improves communication of genetic in-
formation in families. Genetics in Medicine, 10(3), 167–172.
Forrest, L., Delatycki, M., Curnow, L., Skene, L., & Aitken, M. (2010).
Genetic health professionals and the communication of genetic in-
formation in families: practice during and after a genetic consulta-
tion. American Journal of Medical Genetics, 152A, 1458–1466.
Gilbar, R., & Foster, C. (2016). Doctors’ liability to the patient's relatives
in genetic medicine ABC V St George's Healthcare NHS Trust
[2015] EWHC 1394 (Qb). Medical Law Review, 24(1), 112–123.
Hallowell, N., Foster, C., Eeles, R., Ardern-Jones, A., Murday, V., &
Watson, M. (2003). Balancing autonomy and responsibility: the
ethics of generating and disclosing genetic information. Journal of
Medical Ethics, 29(2), 74–79.
Hodgson, J., Metcalfe, S., Gaff, C., Donath, S., Delatycki, M. B.,
Winship, I., et al. (2016). Outcomes of a randomised controlled trial
of a complex genetic counselling intervention to improve family
communication. European Journal of Human Genetics, 24(3), 356.
Joint Committee on Medical Genetics. (2011). Consent and confidential-
ity in genetic practice. London: Royal College of Physicians and
Royal College of Pathologists.
Kääriäinen, H., Hietala, M., Kristoffersson, U., Nippert, I., Rantanen, E.,
Sequeiros, J., … & Kerzin-Storrar, L. (2009). Eurogentest.
Recommendations for genetic counselling related to genetic testing
(final version). Retrieved from http://www.eurogentest.org/index.
php?id=674. Accessed 31 Mar 2017.
Koehly, L. M., Peters, J. A., Kenen, R., Hoskins, L. M., Ersig, A. L.,
Kuhn, N. R., et al. (2009). Characteristics of health information
gatherers, disseminators, and blockers within families at risk of he-
reditary cancer: implications for family health communication inter-
ventions. American Journal of Public Health, 99(12), 2203–2209.
Mendes, Á., Paneque, M., Sousa, L., Clarke, A., & Sequeiros, J. (2016).
How communication of genetic information within the family is
addressed in genetic counselling: a systematic review of research
evidence. European Journal of Human Genetics, 24, 315–325.
Mendes, Á., Metcalfe, A., Paneque, M., Sousa, L., Clarke, A. J., &
Sequeiros, J. (2017). Communication of information about genetic
Dheensa, Lucassen and Fenwick
risks: putting families at the center. Family Process. https://doi.org/
10.1111/famp.12306.
Metcalfe, A., Plumridge, G., Coad, J., Shanks, A., & Gill, P. (2011).
Parents’ and children's communication about genetic risk: a qualita-
tive study, learning from families’ experiences. European Journal of
Human Genetics, 19(6), 640–646.
Mitchell, C., Ploem, M. C., Hennekam, R. C. M., & Kaye, J. (2016). A
duty to warn relatives in clinical genetics: arguably ‘fair just and
reasonable’ in English law? Tottel's Journal of Professional
Negligence, 32(2), 120.
Moran-Ellis, J., Alexander, V. D., Cronin, A., Dickinson, M., Fielding, J.,
& Sleney, J. a. (2006). Triangulation and integration: processes,
claims and implications. Qualitative Research, 6(1), 45–59.
Myers, M., Conrad P., & Blanco, A. et al. (2013). Kintalk.org: a novel
web based communication tool for families with lynch syndrome.
Familial Cancer, 12 (Suppl. 2), S40 (Abstract).
O’Cathain, Murphy, E., Nicholl J. (2010) Three techniques for integrating
data in mixed methods studies. BMJ 341 (sep17 1):c4587–c4587
Ormondroyd, E., Oates, S., Parker, M., Blair, E., & Watkins, H. (2014).
Pre-symptomatic genetic testing for inherited cardiac conditions: a
qualitative exploration of psychosocial and ethical implications.
European Journal of Human Genetics, 22(1), 88.
Plumridge, G., Metcalfe, A., Coad, J., & Gill, P. (2011). Parents’ com-
munication with siblings of children affected by an inherited genetic
condition. Journal of Genetic Counseling, 20(4), 374–383.
Robinson, O. C. (2014). Sampling in interview-based qualitative re-
search: a theoretical and practical guide. Qualitative Research in
Psychology, 11(1), 25–41.
Roggenbuck, J., Temme, R., Pond, D., Baker, J., Jarvis, K., Liu, M., et al.
(2015). The long and short of genetic counseling summary letters: a
case control study. Journal of Genetic Counseling, 24(4), 645–653.
Rowland, E., & Metcalfe, A. (2013). Communicating inherited genetic
risk between parent and child: a meta-thematic synthesis.
International Journal of Nursing Studies, 50(6), 870–880.
Shkedi-Rafid, S., Dheensa, S., Crawford, G., Fenwick, A., & Lucassen,
A. (2014). Defining andmanaging incidental findings in genetic and
genomic practice. Journal of Medical Genetics, 51(11), 715–723.
Stewart, D. W., & Shamdasani, P. N. (2014). Focus groups: Theory and
practice (Vol. 20). Thousand Oaks: Sage Publications.
Stol, Y. H., Menko, F. H., Westerman, M. J., & Janssens, R. M. (2010).
Informing family members about a hereditary predisposition to can-
cer: attitudes and practices among clinical geneticists. Journal of
Medical Ethics, 36(7), 391–395.
Suthers, G. K., Armstrong, J., McCormack, J., & Trott, D. (2006). Letting
the family know: balancing ethics and effectiveness when notifying
relatives about genetic testing for a familial disorder. Journal of
Medical Genetics, 43(8), 665–670.
Tudor-Hart, J. (1971). The inverse care law. The Lancet, 297(7696), 405–
412.
van der Roest, W. P., Pennings, J. M., Bakker, M., van den Berg, M. P., &
van Tintelen, J. P. (2009). Family letters are an effective way to
inform relatives about inherited cardiac disease. American Journal
of Medical Genetics Part A, 149(3), 357–363.
Vaughn, S., Schumm, J. S., & Sinagub, J. (2006). Focus group interviews
in education and psychology. Thousand Oaks: Sage Publications.
Vrijenhoek, T. (2015) In future we'll all access our genomes online.
Bionews, 822 available at http://www.bionews.org.uk/page_
572013.asp. Accessed 29 Mar 2017.
Wiens, M. E., Wilson, B. J., Honeywell, C., & Etchegary, H. (2013). A
family genetic risk communication framework: guiding tool devel-
opment in genetics health services. Journal of Community Genetics,
4(2), 233–242.
Wilson, B. J., & Etchegary, H. (2010). Family communication of geno-
mic information. InHandbook of genomics and the family (pp. 163–
189). New York: Springer US.
Wiseman, M., Dancyger, C., & Michie, S. (2010). Communicating ge-
netic risk information within families: a review. Familial Cancer,
9(4), 691–703.
Wynia, M., & Dunn, K. (2010). Dreams and nightmares: practical and
ethical issues for patients and physicians using personal health re-
cords. The Journal of Law, Medicine & Ethics, 38(1), 64–73.
Limitations and Pitfalls of Using Family Letters to Communicate Genetic Risk: a Qualitative Study with...
